SC
VRTX icon

Syon Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Syon Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Buy
3,640
+77
+2% +$34.1K 0.08% 183
2026
Q1 		$1.59M Buy
3,563
+355
+11% +$166K 0.08% 185
2025
Q4 		$1.45M Buy
3,208
+369
+13% +$159K 0.07% 199
2025
Q3 		$1.11M Sell
2,839
-481
-14% -$201K 0.06% 233
2025
Q2 		$1.48M Buy
3,320
+13
+0.4% +$5.99K 0.1% 147
2025
Q1 		$1.6M Buy
3,307
+947
+40% +$441K 0.13% 116
2024
Q4 		$950K Sell
2,360
-157
-6% -$72.8K 0.09% 165
2024
Q3 		$1.17M Sell
2,517
-24
-0.9% -$11.5K 0.1% 147
2024
Q2 		$1.19M Buy
2,541
+71
+3% +$30.8K 0.11% 135
2024
Q1 		$1.03M Buy
2,470
+194
+9% +$82K 0.1% 150
2023
Q4 		$926K Buy
2,276
+111
+5% +$41K 0.09% 155
2023
Q3 		$753K Buy
+2,165
New +$757K 0.09% 134

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Syon Capital's VRTX Position: Q2 2026 in Review

Syon Capital increased its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q2 2026, buying an estimated $34.1K and bringing the position to 3,640 shares worth $1.81M. The position accounts for 0.08% of the portfolio, ranked #183.

Syon Capital first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Syon Capital held 3,640 shares of Vertex Pharmaceuticals worth $1.81M as of Q2 2026.
  • Syon Capital bought 77 Vertex Pharmaceuticals shares in Q2 2026, an estimated $34.1K.
  • Vertex Pharmaceuticals made up 0.08% of Syon Capital's portfolio in Q2 2026, its #183 holding.
  • Syon Capital first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.